Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

A 12-YEAR-OLD boy has been left blind because he would only eat burgers and doughnuts. The unnamed child who lived in the US ...

PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited is making significant strides in its ...

ANX007 significantly reduces vision loss risk in geographic atrophy patients by 72% with monthly treatment. The drug targets the complement system, blocking C1q to prevent neurodegeneration and ...

Phase 3 DRAGON study aims to confirm Tinlarebant's efficacy, with potential as the first treatment for Stargardt disease and geographic atrophy. In an interview with Ophthalmology Times, Quan Dong ...

Next in the pipeline is OCS-05, a disease-modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy ...

SMA is a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy. Despite progress in developing treatments targeting motor neuron loss ...

after the clinical-stage biotech company said a late-stage trial of a treatment for spinal muscular atrophy met its main goal. The Phase 3 trial of apitegromab showed statistically significant ...